Journal of Neonatal Surgery
ISSN(Online): 2226-0439
Vol. 14, Issue 7s (2025)
https://www.jneonatalsurg.com

OPEN ACCESS

Norfloxacin-Loaded Lipospheres: A Novel Lipid-Based Approach for Enhanced Solubility, Stability and Bioavailability

Rajni Tanwar[*1], Arshdeep Singh Brar[2], Puja Gulati[3]

[*1]Associate Professor, School of Pharmacy, Desh Bhagat University, Mandi Gobindgarh, Punjab.

[2]Research Scholar, School of Pharmacy, Desh Bhagat University, Mandi Gobindgarh, Punjab.

Email ID: Robinsindhu94@gmail.com

[3]Professor & Principal, School of Pharmacy, Desh Bhagat University, Mandi Gobindgarh, Punjab.

Email ID: Puja_duggal@yahoo.co.in

***Corresponding Author:**

Email ID: rajnitanwar059@gmail.com, Orcid ID: 0009-0003-3391-2153

Cite this paper as: Rajni Tanwar, Arshdeep Singh Brar, Puja Gulati, (2025) Norfloxacin-Loaded Lipospheres: A Novel Lipid-Based Approach for Enhanced Solubility, Stability and Bioavailability. *Journal of Neonatal Surgery*, 14 (7s), 618-632.

ABSTRACT

Norfloxacin, a second-generation fluoroquinolone exhibits potent antibacterial activity but suffers from poor oral bioavailability due to limited solubility, permeability and extensive first-pass metabolism. Liposphere-based drug delivery systems offer a promising approach to overcoming these limitations by encapsulating norfloxacin in lipid matrices enhancing its solubility, stability and controlled release. This review explores the formulation strategies, characterization and evaluation of norfloxacin-loaded lipospheres. Various preparation techniques including solvent evaporation, melt dispersion and supercritical fluid technology are discussed highlighting their impact on encapsulation efficiency, particle size and drug release kinetics. The pharmacokinetic advantages of lipospheres including improved absorption, prolonged systemic circulation and reduced dosing frequency are analyzed through in vitro and in vivo studies. Furthermore, the potential clinical applications of lipospheres in bacterial infections, their safety considerations and future prospects in lipid-based antibiotic delivery are examined. Lipospheres present a viable strategy for enhancing norfloxacin's therapeutic effectiveness, minimizing bacterial resistance and improving patient compliance. Further research into stability optimization, large-scale production and clinical validation is warranted to facilitate the transition of liposphere-based formulations into mainstream pharmaceutical applications.

Keywords: *Norfloxacin, Lipospheres, Oral Bioavailability, Drug Delivery, Pharmacokinetics, Antibiotic Therapy*

1. INTRODUCTION

Norfloxacin, a second-generation fluoroquinolone antibiotic, has been widely used in clinical settings to treat bacterial infections, particularly those associated with the urinary tract, gastrointestinal system, and respiratory tract.(1) It is known for its potent bactericidal activity, primarily achieved by inhibiting bacterial DNA gyrase and topoisomerase IV—two critical enzymes responsible for DNA replication and repair in bacteria.(2) By disrupting these enzymatic functions, norfloxacin prevents bacterial cell division, leading to cell death and effective infection control. However, despite its broad-spectrum activity and therapeutic potential, norfloxacin suffers from poor oral bioavailability, significantly limiting its clinical efficacy.(3) This limitation arises from multiple pharmacokinetic challenges, including poor aqueous solubility, limited intestinal permeability, and significant first-pass metabolism, all of which contribute to reduced systemic drug concentrations following oral administration. (4)Oral bioavailability plays a crucial role in determining the therapeutic effectiveness of a drug, as it dictates the proportion of the administered dose that reaches systemic circulation in an active form. In the case of norfloxacin, its low solubility in gastrointestinal fluids leads to incomplete dissolution, thereby reducing the extent of absorption.(5)

As a Biopharmaceutics Classification System (BCS) Class IV drug, norfloxacin exhibits both poor solubility and poor permeability, making it particularly challenging to formulate an effective oral dosage form. (6)Additionally, the drug undergoes extensive first-pass metabolism in the liver, further decreasing its bioavailability. As a result, higher doses are

often required to achieve therapeutic plasma concentrations, which, in turn, increase the risk of adverse effects such as nausea, diarrhea, dizziness, and, in some cases, antibiotic resistance due to prolonged exposure at suboptimal concentrations. (7)One of the major concerns with conventional norfloxacin formulations is their inability to achieve sustained and efficient drug release, leading to fluctuations in plasma drug levels. This variability in drug concentration not only affects therapeutic outcomes but also contributes to the development of bacterial resistance, a growing global health concern.(8)

To overcome these limitations, extensive research has been conducted to improve the pharmacokinetic profile of norfloxacin, focusing on strategies that enhance its solubility, stability, and absorption in the gastrointestinal tract. Various formulation approaches, including solid dispersions, inclusion complexes, liposomes, nanoparticles, and lipid-based carriers, have been investigated to optimize its oral delivery. (9)Among these, lipid-based drug delivery systems, particularly lipospheres, have gained significant attention due to their ability to improve drug solubility, protect against enzymatic degradation, and facilitate controlled drug release. Lipospheres are lipid-based colloidal carriers designed to encapsulate hydrophobic drugs within a solid lipid core stabilized by surfactants or emulsifiers.(10) These carriers provide a versatile platform for drug delivery, offering several advantages over conventional dosage forms. One of the key benefits of lipospheres is their ability to enhance the solubility and dissolution rate of poorly water-soluble drugs, thereby improving their absorption in the gastrointestinal tract.(11) Unlike other lipid-based carriers such as liposomes, which consist of bilayered vesicles, lipospheres are characterized by a single lipid matrix, making them more stable and suitable for oral administration. The hydrophobic nature of the lipid core allows for the efficient encapsulation of norfloxacin, protecting it from degradation and reducing its susceptibility to metabolic inactivation.(12)

Another advantage of lipospheres is their ability to modulate drug release, ensuring sustained therapeutic levels in systemic circulation. Conventional norfloxacin formulations often result in rapid drug clearance, necessitating frequent dosing to maintain effective plasma concentrations. However, lipospheres can be engineered to provide controlled release, minimizing fluctuations in drug levels and reducing dosing frequency.(13) This sustained-release profile not only enhances therapeutic efficacy but also improves patient compliance by reducing the burden of multiple daily doses. Additionally, lipospheres have been shown to promote drug permeability across biological membranes, overcoming the absorption barriers that limit the oral bioavailability of norfloxacin. The choice of lipid excipients and formulation parameters plays a crucial role in determining the efficiency of liposphere-based drug delivery. (14)

Various solid lipids, including stearic acid, glyceryl monostearate, and tristearin, have been investigated for their ability to encapsulate norfloxacin and modulate its release characteristics. The selection of emulsifiers and surfactants, such as lecithin, poloxamers, and Tween derivatives, also influences the stability and dispersibility of lipospheres in gastrointestinal fluids. The optimization of formulation variables, including lipid concentration, surfactant ratio, and homogenization techniques, is essential to achieve the desired physicochemical properties and bioavailability enhancement.(15) In addition to their pharmaceutical benefits, lipospheres offer a promising approach for targeted drug delivery, potentially improving the therapeutic index of norfloxacin. By modifying the surface properties of lipospheres, it is possible to achieve site-specific drug delivery, directing norfloxacin to the site of infection while minimizing off-target effects.(16) This targeted approach can be particularly beneficial in cases of bacterial infections localized in specific regions, such as the gastrointestinal tract or urinary system. Furthermore, lipospheres can be co-loaded with additional bioactive agents, such as permeation enhancers or bioavailability boosters, to further enhance drug absorption and therapeutic outcomes. Despite the advantages of liposphere-based delivery, several challenges remain in the development of optimized formulations.(17) Ensuring the physical and chemical stability of lipospheres during storage is critical, as lipid oxidation and drug leakage can affect the integrity of the formulation. Additionally, the scalability and cost-effectiveness of liposphere production need to be considered for successful commercial translation. Advances in lipid nanotechnology and formulation techniques continue to drive the development of novel liposphere systems, with ongoing research focused on improving their pharmacokinetic and pharmacodynamic profiles. Given the potential of lipospheres in enhancing the oral bioavailability of norfloxacin, further investigation is warranted to optimize formulation parameters and evaluate their in vivo performance.(18)

The integration of advanced characterization techniques, such as differential scanning calorimetry (DSC), Fourier-transform infrared spectroscopy (FTIR), and dynamic light scattering (DLS), can provide valuable insights into the physicochemical properties of lipospheres and their drug release mechanisms. Additionally, pharmacokinetic and pharmacodynamic studies in preclinical and clinical settings are essential to validate the efficacy and safety of liposphere-based norfloxacin formulations. This review article will explore norfloxacin-loaded lipospheres as a novel approach to overcoming the challenges associated with oral drug delivery. By discussing the formulation strategies, in vitro and in vivo assessments, and potential clinical applications, this review aims to provide comprehensive insights into the role of lipospheres in enhancing the bioavailability and therapeutic effectiveness of norfloxacin.(19)



Fig 1: Pharmacokinetic Barriers of Norfloxacin & How Lipospheres Solve Them(20)

This diagram illustrates the key challenges in Norfloxacin oral delivery, including poor solubility, low permeability, and first-pass metabolism, and how liposphere-based encapsulation addresses these issues. Through enhanced solubility, improved permeation, and metabolic protection, lipospheres ultimately lead to improved bioavailability**.**

2. LIPOSPHERE-BASED DRUG DELIVERY SYSTEM

Liposphere-based drug delivery has emerged as a promising approach for improving the solubility, stability, and bioavailability of poorly water-soluble drugs like norfloxacin. These systems leverage lipid-based carriers to enhance drug encapsulation and controlled release, providing a more efficient oral drug delivery platform.(21)

2.1 Definition and Advantages of Lipospheres

Lipospheres are lipid-based colloidal carriers composed of a solid lipid core stabilized by an outer surfactant layer. Unlike liposomes, which have aqueous compartments, lipospheres provide a more stable matrix for encapsulating hydrophobic drugs, ensuring enhanced solubility and controlled drug release. They offer several advantages, including improved drug protection from enzymatic degradation, prolonged systemic circulation, and the ability to enhance drug permeation across biological membranes. Additionally, lipospheres exhibit biocompatibility, reduced systemic toxicity, and the potential for targeted drug delivery, making them a suitable option for optimizing oral drug formulations.(22)



Fig 2: Advantages of Lipospheres in Norfloxacin Drug Delivery(23)

The benefits of liposphere-based drug delivery are summarized in this figure highlighting improvements in solubility, stability, bioavailability and patient compliance

2.2 Composition and Formulation of Lipospheres

The formulation of lipospheres involves the selection of appropriate lipid carriers, surfactants, and stabilizers to achieve the desired drug-loading efficiency and release profile. Solid lipids such as stearic acid, glyceryl monostearate, and tristearin are commonly used as the core matrix, providing a stable environment for drug entrapment.(24) Surfactants like lecithin, poloxamers, and Tween derivatives help stabilize the lipid matrix, ensuring uniform dispersion in aqueous media. The choice of lipid and surfactant significantly influences the size, stability, and drug release kinetics of the lipospheres. Various preparation techniques, including solvent evaporation, melt dispersion, and high-pressure homogenization, are utilized to optimize formulation properties.(25)

2.3 Mechanism of Drug Encapsulation and Release

Drug encapsulation in lipospheres occurs through the incorporation of the active pharmaceutical ingredient within the solid lipid core, where it is either molecularly dispersed or present as a finely distributed suspension. The lipid matrix acts as a protective barrier, shielding the drug from environmental degradation and enzymatic metabolism. Upon oral administration, lipospheres undergo gradual degradation in the gastrointestinal tract, facilitating sustained and controlled drug release.(26) The release mechanism is influenced by factors such as lipid composition, particle size, and external conditions such as pH and enzymatic activity. Typically, drug release occurs through diffusion, lipid matrix erosion, or a combination of both, ensuring prolonged systemic exposure and improved bioavailability.(27)

3. PREPARATION OF NORFLOXACIN-LOADED LIPOSPHERES

The formulation of norfloxacin-loaded lipospheres involves a meticulous selection of lipid carriers and surfactants, followed by precise manufacturing techniques to ensure optimal drug encapsulation, stability, and controlled release. The choice of excipients and preparation method significantly influences the physicochemical properties, bioavailability, and therapeutic efficacy of the final formulation.

3.1 Selection of Lipid Carriers and Surfactants

The lipid matrix serves as the core structural component of lipospheres and plays a crucial role in determining drug solubility, release kinetics, and stability. Solid lipids such as stearic acid, glyceryl monostearate, tristearin, and cetyl alcohol are commonly employed due to their biocompatibility and ability to form stable lipid matrices.(28) These lipids provide a hydrophobic environment that enhances the solubilization of norfloxacin, preventing its premature degradation while facilitating sustained drug release. Surfactants act as stabilizing agents, ensuring the uniform dispersion of lipospheres in aqueous media while preventing aggregation. The selection of an appropriate surfactant depends on its hydrophilic-lipophilic balance (HLB) value, which governs its emulsification efficiency.(29) Non-ionic surfactants such as Tween 80, Span 60, poloxamers, and lecithin are widely utilized due to their ability to reduce interfacial tension and enhance drug permeability across biological membranes. The combination of solid lipids with an optimal surfactant concentration ensures the formation of stable, monodisperse lipospheres with high drug loading efficiency shown in table 1.

Table 1: Common Lipid Carriers and Surfactants Used in Norfloxacin Lipospheres

Lipid Carriers		
Lipid Carriers	**Melting Point (°C)**	**Role/Advantages**
Stearic Acid	69-70	Stable lipid matrix, excellent drug retention
Glyceryl Monostearate	58–59	Biocompatibility, sustained drug release
Tristearin	54–57	Good encapsulation efficiency and stability

Cetyl Alcohol	49–52	Enhanced encapsulation efficiency
Surfactants		
Surfactants	**HLB Value**	**Function**
Tween 80	15.0	Emulsification, enhanced permeability
Span 60	4.7	Stabilization, particle size control
Poloxamers	12–18	Surfactant stability, bioavailability enhancer
Lecithin	4–9	Biocompatibility, permeability enhancement

3.2 Methods of Liposphere Preparation

The fabrication of lipospheres involves multiple techniques, each designed to optimize particle size, encapsulation efficiency, and drug release characteristics. The most widely adopted methods for the preparation of norfloxacin-loaded lipospheres include solvent evaporation, melt dispersion, and supercritical fluid technology shown in table 2.(30)

Table 2: Comparative Overview of Liposphere Preparation Methods

Method	Solvent Use	Advantages	Limitations
Solvent Evaporation	Organic solvents (e.g., chloroform, dichloromethane)	High drug encapsulation, simplicity	Residual solvents, porous particles
Melt Dispersion	No organic solvents	High encapsulation efficiency, controlled release	Limited to thermally stable drugs, precise temperature control required
Supercritical Fluid Technology	Solvent-free	High purity, controlled particle size	Specialized equipment, scalability challenges

A. Solvent Evaporation Method

The solvent evaporation technique is a widely employed method for the preparation of lipospheres due to its simplicity and efficiency in encapsulating hydrophobic drugs. This process involves dissolving the lipid and norfloxacin in an organic solvent such as dichloromethane or chloroform, followed by emulsification in an aqueous phase containing a surfactant. High-speed homogenization or ultrasonication is applied to reduce droplet size, ensuring the formation of a stable emulsion.(31) The organic solvent is then removed by continuous stirring under reduced pressure or ambient conditions, leading to the precipitation of solid lipid nanoparticles containing the entrapped drug. A critical parameter in this technique is the solvent-to-lipid ratio, as it affects drug loading and particle stability. Rapid solvent removal results in the formation of porous structures, which may influence drug release kinetics. Moreover, optimizing homogenization speed and emulsifier concentration is crucial for achieving uniform particle size distribution and preventing drug crystallization, which could compromise bioavailability.(32)

B. Melt Dispersion Method

The melt dispersion method is another commonly used approach, particularly suitable for thermally stable drugs. In this process, the lipid carrier is heated above its melting point, allowing the drug to dissolve within the molten lipid matrix. This molten phase is then dispersed into an aqueous surfactant solution under high-shear homogenization, leading to the formation of an emulsion.(32) Upon cooling, the lipid recrystallizes, entrapping norfloxacin within the solid lipid core. This method provides several advantages, including the avoidance of organic solvents, enhanced encapsulation efficiency, and the potential for sustained drug release. However, maintaining precise temperature control is critical, as excessive heat can degrade norfloxacin, whereas inadequate melting can lead to incomplete drug incorporation. Additionally, the cooling rate influences particle morphology and crystallinity, which directly impact drug release kinetics. (33)A slow cooling process typically results in well-structured lipospheres with controlled drug diffusion, while rapid solidification may create amorphous regions that enhance drug solubility but alter stability.(34)

C. Supercritical Fluid Technology

Supercritical fluid (SCF) technology is an advanced technique that offers solvent-free preparation of lipospheres, minimizing environmental and residual solvent toxicity concerns. This method involves the use of supercritical carbon dioxide ($scCO_2$) as a processing medium, where the drug and lipid are dissolved or dispersed under controlled temperature and pressure conditions. Upon rapid depressurization, the solubilized components undergo nucleation and particle formation, yielding nanosized lipospheres with high purity and controlled drug release properties.(35) The SCF process can be executed through various approaches, such as rapid expansion of supercritical solution (RESS), supercritical anti-solvent (SAS) precipitation, and gas-assisted melting atomization (GAMA). The RESS technique involves dissolving the drug-lipid mixture in supercritical CO_2, followed by sudden depressurization through a nozzle, leading to rapid particle formation. The SAS method, on the other hand, involves introducing an organic solution of the drug and lipid into a supercritical CO_2 environment, resulting in the precipitation of solid particles as the solvent diffuses into the SCF phase. The GAMA technique utilizes supercritical CO_2 to atomize molten lipids into fine droplets, which solidify upon cooling to form lipospheres.(36)

SCF technology provides several advantages, including precise control over particle size distribution, high drug loading capacity, and the ability to produce solvent-free formulations. However, the requirement for specialized equipment and high-pressure conditions poses challenges in large-scale manufacturing. Additionally, optimizing process parameters such as temperature, pressure, and CO_2 flow rate is essential to achieve reproducible particle characteristics and enhance the oral bioavailability of norfloxacin. The selection of an appropriate preparation technique depends on multiple factors, including drug stability, encapsulation efficiency, scalability, and regulatory considerations. Each method offers distinct advantages and limitations, necessitating careful optimization to develop a robust liposphere-based formulation for norfloxacin. The incorporation of advanced characterization techniques and in vivo pharmacokinetic studies further ensures the efficacy and safety of these formulations for clinical applications.(37)

4. CHARACTERIZATION OF NORFLOXACIN-LOADED LIPOSPHERES

The evaluation of norfloxacin-loaded lipospheres involves multiple physicochemical and biopharmaceutical assessments to ensure their efficacy, stability, and suitability for oral drug delivery. These characterizations provide crucial insights into the formulation's performance in enhancing drug bioavailability, regulating release kinetics, and improving pharmacokinetic parameters shown in table 3.(9, 38)

Table 3: Parameters for Evaluating Norfloxacin-Loaded Lipospheres(38)

Parameter	**Method of Analysis**	**Significance**
Particle Size and Morphology	DLS, TEM, SEM	Influences drug dissolution, absorption, and stability
Encapsulation Efficiency (EE)	Ultracentrifugation, HPLC	Determines efficiency of drug encapsulation
Drug Loading (DL)	HPLC	Indicates the drug content per weight of formulation

Zeta Potential (Surface Charge)	Dynamic Light Scattering (DLS)	Stability, circulation time, and interaction with membranes
In Vitro Drug Release	Dissolution (HPLC/UV analysis)	Determines controlled release profile and duration

A. Particle Size and Morphology

The size and morphology of lipospheres significantly influence drug absorption, stability, and release behavior. Particle size determines the surface area available for drug dissolution and interaction with biological membranes, with smaller particles exhibiting improved solubility and enhanced gastrointestinal permeability. Lipospheres are typically characterized using dynamic light scattering (DLS) or laser diffraction techniques, which measure the hydrodynamic diameter and polydispersity index (PDI). (39)A lower PDI indicates uniformity in particle size distribution, contributing to predictable drug release and absorption. Scanning electron microscopy (SEM) and transmission electron microscopy (TEM) provide detailed morphological analysis, revealing the surface texture and structural integrity of lipospheres. Spherical morphology with a smooth surface indicates successful encapsulation, while irregularities may suggest lipid crystallization or phase separation. The formulation method, lipid composition, and processing conditions—such as homogenization speed and ultrasonication—directly impact particle size and morphology. Optimal formulation parameters ensure reduced aggregation and increased dispersion in gastrointestinal fluids, facilitating enhanced drug transport across intestinal epithelium.(40)

B. Encapsulation Efficiency and Drug Loading

Encapsulation efficiency (EE) and drug loading (DL) are critical parameters that determine the proportion of norfloxacin successfully entrapped within the lipid matrix and the drug concentration per unit mass of lipospheres, respectively. High EE values indicate efficient drug incorporation, minimizing drug loss during formulation. EE is commonly assessed using ultracentrifugation followed by high-performance liquid chromatography (HPLC) analysis of the supernatant to quantify the unencapsulated drug fraction.(41) Encapsulation efficiency is influenced by lipid type, surfactant concentration, and preparation technique. Hydrophobic interactions between norfloxacin and lipid matrices enhance drug retention, while excess surfactant may disrupt encapsulation by increasing drug solubility in the aqueous phase. Optimizing the lipid-to-drug ratio and selection of stabilizers such as phospholipids or poloxamers can significantly improve EE. Drug loading, calculated as the amount of drug per total liposphere weight, determines the therapeutic potential of the formulation. Higher DL values ensure efficient drug delivery while maintaining lipid stability.(42, 43)

C. Surface Charge and Stability

The zeta potential of lipospheres, measured using electrophoretic light scattering (ELS), determines their surface charge and stability in biological environments. A high absolute zeta potential (±30 mV) confers electrostatic repulsion between particles, preventing aggregation and ensuring colloidal stability. Lipid composition, ionic strength, and surfactant selection play key roles in modulating surface charge.(44) Negatively charged lipospheres, often achieved by incorporating anionic lipids such as phosphatidylserine, exhibit prolonged systemic circulation by evading opsonization and premature clearance. Stability assessments include evaluating changes in particle size, encapsulation efficiency, and drug release profiles over time under various storage conditions. Differential scanning calorimetry (DSC) and X-ray diffraction (XRD) techniques help determine the crystallinity of lipids, as amorphous lipid structures favor controlled drug release, while excessive crystallization may lead to drug expulsion. Fourier-transform infrared spectroscopy (FTIR) is employed to assess possible interactions between norfloxacin and lipid excipients, ensuring the absence of chemical degradation or incompatibility.(45)

D. In Vitro Drug Release Studies

Controlled drug release is essential for maintaining therapeutic drug concentrations over an extended period, reducing dosing frequency, and improving patient compliance. In vitro drug release studies simulate gastrointestinal conditions to evaluate the dissolution and diffusion behavior of norfloxacin from lipospheres. These studies are typically performed using the dialysis bag method or USP dissolution apparatus, where lipospheres are suspended in simulated gastric and intestinal fluids, and drug release is quantified at specific time intervals using HPLC or UV spectrophotometry. (46)Drug release kinetics are influenced by lipid composition, matrix structure, and external factors such as pH and enzymatic degradation. Lipospheres often exhibit biphasic release patterns, characterized by an initial burst release followed by sustained drug diffusion. The burst effect results from the rapid desorption of surface-associated drug molecules, while the subsequent controlled release phase is governed by lipid matrix erosion or diffusion through lipid channels. Mathematical modeling, including Higuchi, Korsmeyer-Peppas, and first-order kinetic models, helps elucidate the mechanisms underlying norfloxacin release from lipospheres. The integration of these characterization techniques ensures that norfloxacin-loaded lipospheres exhibit optimal

properties for enhanced oral bioavailability. By controlling particle size, optimizing encapsulation efficiency, ensuring colloidal stability, and fine-tuning release kinetics, liposphere formulations offer a promising approach for improving the therapeutic effectiveness of norfloxacin in clinical applications.(47)

5. EVALUATION OF ORAL BIOAVAILABILITY ENHANCEMENT

Optimizing the oral bioavailability of norfloxacin requires comprehensive pharmacokinetic evaluation to understand the impact of liposphere-based formulations on drug absorption, distribution, metabolism, and elimination.(48) The encapsulation of norfloxacin within lipid-based carriers aims to improve solubility, enhance intestinal permeability, and prolong systemic circulation, ultimately leading to increased therapeutic efficacy. These improvements are systematically assessed through pharmacokinetic studies in animal models, in vivo absorption analysis, and direct comparison with conventional norfloxacin formulations to establish the superiority of liposphere-based drug delivery.(49)

5. 1 Pharmacokinetic Studies in Animal Models

Pharmacokinetic evaluations in animal models provide a crucial framework for assessing the bioavailability enhancement achieved by lipospheres. These studies typically involve the oral administration of norfloxacin-loaded lipospheres to rodents or larger mammals, followed by serial blood sampling to determine plasma drug concentrations at specific time points. Analytical techniques such as high-performance liquid chromatography (HPLC) or liquid chromatography-mass spectrometry (LC-MS) are employed to quantify drug levels and evaluate key pharmacokinetic parameters, including maximum plasma concentration (C_max), time to peak concentration (T_max), area under the plasma concentration-time curve (AUC), and elimination half-life (t_1/2) shown in figure 3.(50)

The encapsulation of norfloxacin within lipospheres significantly alters its pharmacokinetic behavior by modulating drug release and absorption kinetics. The lipid matrix protects the drug from enzymatic degradation in the gastrointestinal tract, thereby reducing pre-systemic metabolism. Additionally, the controlled-release nature of lipospheres ensures a gradual and sustained drug release, preventing rapid clearance and maintaining prolonged therapeutic levels in circulation. Studies have demonstrated that lipospheres increase the AUC of norfloxacin, reflecting enhanced systemic exposure, while also extending the elimination half-life, reducing the need for frequent dosing. Such pharmacokinetic advantages contribute to improved therapeutic outcomes and better patient compliance shown in table 4.(51)

Table 4: Comparative Pharmacokinetic Parameters of Liposphere-based versus Conventional Norfloxacin Formulations

Pharmacokinetic Parameter	Conventional Norfloxacin	Norfloxacin-loaded Lipospheres	Enhancement (%)
C_max (µg/mL)	1.2	3.4	183%
T_max (hours)	1.5	4.0	Delayed release
AUC (µg·h/mL)	4.8	12.6	163%
t_½ (hours)	4.2	8.5	167%



Fig 3: Sankey Diagram illustrating Comparative Drug Bioavailability Flow (Conventional vs. Liposphere-Based Norfloxacin)

It illustrates the comparative drug bioavailability between conventional norfloxacin and liposphere-based formulations, highlighting improved absorption, reduced first-pass metabolism, and prolonged systemic circulation.

5.2 In Vivo Absorption and Drug Distribution

The absorption of norfloxacin from the gastrointestinal tract is a major limiting factor in its oral bioavailability, as it exhibits poor solubility and permeability. Liposphere enhance this process through multiple mechanisms, primarily by increasing the dissolution of the drug in gastric and intestinal fluids. The lipid core of the formulation facilitates the formation of mixed micelles in the presence of bile salts and digestive enzymes, thereby solubilizing norfloxacin in a lipid-rich environment that enhances passive diffusion across the intestinal epithelium. Another critical mechanism involves the inhibition of efflux transporters such as P-glycoprotein (P-gp), which actively pump norfloxacin out of enterocytes, reducing its net absorption. Liposphere, due to their lipid composition, can effectively inhibit P-gp activity, leading to increased intracellular drug retention and improved bioavailability. Additionally, liposphere promote transcellular transport by fusing with the lipid bilayer of enterocytes, enabling norfloxacin to bypass the restrictive paracellular pathways and enter systemic circulation more efficiently.(52)

Following absorption, the biodistribution of norfloxacin is also significantly influenced by liposphere encapsulation. Conventional formulations exhibit limited tissue penetration due to the hydrophilic nature of norfloxacin, leading to rapid renal excretion. In contrast, liposphere enhance the drug's affinity for lipophilic tissue compartments, facilitating higher drug accumulation in infection-prone regions such as the kidneys, liver, and gastrointestinal mucosa. This preferential tissue targeting enhances therapeutic efficacy while minimizing off-target effects. Moreover, the sustained-release profile of liposphere ensures prolonged drug retention, reducing fluctuations in plasma concentrations and maintaining steady-state therapeutic levels.(53)

5.3 Comparison with Conventional Norfloxacin Formulations

Traditional oral formulations of norfloxacin, including immediate-release tablets and capsules, exhibit poor and inconsistent bioavailability due to their limited solubility and rapid elimination. Typically, norfloxacin demonstrates an oral bioavailability of only 30-40%, requiring frequent dosing to achieve and maintain effective plasma concentrations. However, this dosing strategy often leads to suboptimal therapeutic outcomes, as fluctuating drug levels contribute to bacterial resistance and increased gastrointestinal side effects. The integration of liposphere-based delivery systems has demonstrated significant improvements in the pharmacokinetic profile of norfloxacin. Studies comparing conventional formulations with liposphere-loaded norfloxacin reveal notable increases in C_max and AUC, reflecting enhanced absorption and systemic exposure. Additionally, T_max is typically delayed in liposphere formulations, indicating a controlled and sustained drug release mechanism. The prolonged elimination half-life further supports the reduced dosing frequency required to maintain therapeutic efficacy, thereby improving patient adherence to antibiotic therapy.

Moreover, the ability of liposphere to minimize first-pass metabolism and reduce enzymatic degradation enhances the overall bioavailability of norfloxacin, making lower doses sufficient to achieve the desired therapeutic effect. The improved solubility, permeability, and distribution profile of liposphere-encapsulated norfloxacin positions this formulation as a superior alternative to conventional oral dosage forms. By leveraging these pharmacokinetic advantages, liposphere-based norfloxacin formulations hold great potential for clinical translation. Future studies should focus on optimizing lipid composition, exploring targeted delivery modifications, and conducting extensive in vivo evaluations to confirm their efficacy and safety.(54)

6. STABILITY AND STORAGE CONSIDERATIONS

The stability of liposphere-based formulations is a critical factor that influences their efficacy, shelf-life, and overall pharmaceutical applicability. Ensuring the physical and chemical stability of norfloxacin-loaded liposphere is essential for maintaining drug integrity, preventing premature degradation, and preserving the controlled-release properties of the formulation. Various factors, including temperature, humidity, oxidative degradation, and interactions between the lipid matrix and the encapsulated drug, can significantly impact the stability profile of liposphere. Proper storage conditions and stability assessments are therefore crucial for optimizing the formulation for long-term clinical use.(55)

A. Physical and Chemical Stability of Liposphere

The physical stability of liposphere is largely dependent on the characteristics of the lipid carrier, emulsifier, and drug-lipid interactions. One of the primary concerns in liposphere stability is the potential for particle aggregation or coalescence over time, which may result in increased particle size, phase separation, and compromised drug release profiles. Factors such as inappropriate surfactant concentration, temperature fluctuations, and prolonged storage can contribute to instability, leading to altered pharmacokinetics and reduced therapeutic efficacy. Dynamic light scattering (DLS) and zeta potential measurements are commonly used to monitor the physical stability of liposphere by assessing changes in particle size distribution and surface charge over time.(56)

Chemical stability is another critical aspect, as norfloxacin is susceptible to hydrolysis, oxidation, and photodegradation, which can lead to loss of potency. Liposphere provide a protective lipid matrix that shields norfloxacin from environmental stressors, reducing the likelihood of degradation. However, lipid oxidation remains a challenge, particularly in formulations containing unsaturated fatty acids, which are prone to peroxidation. The incorporation of antioxidants such as tocopherols or

butylated hydroxytoluene (BHT) within the lipid phase can mitigate oxidative degradation and improve chemical stability. Spectroscopic techniques such as Fourier-transform infrared (FTIR) spectroscopy and differential scanning calorimetry (DSC) are commonly employed to assess chemical interactions between norfloxacin and the lipid excipients, ensuring compatibility and stability during storage.(57)

B. Shelf-Life Assessment

Determining the shelf-life of norfloxacin-loaded lipospheres involves accelerated and long-term stability studies under controlled conditions. These studies are conducted in accordance with International Council for Harmonisation (ICH) guidelines, which recommend evaluating formulation stability under varying temperature and humidity conditions. Accelerated stability testing typically involves storing the formulation at elevated temperatures (e.g., 40°C ± 2°C with 75% relative humidity) to predict long-term stability within a shorter duration. Long-term stability studies, on the other hand, assess formulation integrity over an extended period at controlled room temperature and refrigeration conditions.(58)

Key stability parameters monitored during shelf-life assessments include drug content retention, particle size distribution, zeta potential, encapsulation efficiency, and drug release profiles. A decline in encapsulation efficiency or a significant change in drug release kinetics over time may indicate instability, necessitating modifications in lipid composition or storage conditions. Moreover, microbial stability assessments are performed to ensure the formulation remains free from microbial contamination throughout its shelf-life, particularly in liquid or semi-solid liposphere dispersions.(59)

C. Impact of Storage Conditions on Drug Release

Storage conditions significantly influence the drug release characteristics of lipospheres. Temperature variations can affect the crystallinity and polymorphic transitions of the lipid matrix, altering the drug diffusion rate and release kinetics. For instance, prolonged exposure to high temperatures can lead to lipid melting, recrystallization, or phase separation, resulting in burst drug release or incomplete drug retention. Conversely, storage at excessively low temperatures may induce lipid crystallization, restricting drug mobility and delaying release upon administration. The relative humidity of the storage environment also plays a crucial role, as excessive moisture exposure can lead to hydrolysis of norfloxacin or destabilization of lipid-based carriers. Encapsulation in moisture-resistant packaging, such as aluminum blister packs or airtight glass vials, can help minimize these effects. Additionally, the incorporation of lyophilization (freeze-drying) techniques can improve the stability of lipospheres by reducing moisture content and enhancing solid-state preservation.(60)

To ensure optimal performance, liposphere formulations should be stored under recommended conditions, typically at controlled room temperature (15–25°C) or under refrigeration (2–8°C) depending on the lipid composition. Proper packaging, along with the inclusion of stabilizers and cryoprotectants, can further enhance stability and extend the shelf-life of norfloxacin-loaded lipospheres.(61) By addressing these stability challenges, liposphere formulations can be effectively optimized for long-term storage, ensuring consistent bioavailability, controlled drug release, and therapeutic efficacy over time. Further research into advanced stabilization techniques, such as nanostructured lipid carriers and polymer-coated lipospheres, may provide additional improvements in stability and formulation robustness.(62)

7. THERAPEUTIC POTENTIAL AND CLINICAL APPLICATIONS

The development of liposphere-based drug delivery systems for norfloxacin represents a significant advancement in antibiotic therapy, addressing critical limitations associated with conventional oral formulations. By enhancing bioavailability, prolonging systemic circulation, and enabling controlled drug release, lipospheres offer a promising strategy to improve the therapeutic efficacy of norfloxacin. Their potential applications extend beyond standard bacterial infections, providing new opportunities for treating resistant pathogens, site-specific infections, and minimizing adverse drug reactions. Moreover, the improved pharmacokinetic profile and targeted delivery mechanisms of lipospheres open new avenues for clinical applications in both acute and chronic infectious diseases.(63)

7. 1 Potential Benefits in Bacterial Infections

Norfloxacin is primarily used to treat infections of the urinary tract, gastrointestinal system, and respiratory tract, but its therapeutic effectiveness is often compromised by poor absorption, rapid renal excretion, and limited tissue penetration. Lipospheres offer a solution by significantly enhancing drug solubility and promoting better mucosal adhesion, thereby increasing local drug concentrations at the infection site. This targeted approach is particularly advantageous in urinary tract infections (UTIs), where liposphere-encapsulated norfloxacin can achieve sustained drug levels in the bladder and kidneys, leading to improved bacterial eradication and reduced recurrence rates. Additionally, the controlled release properties of lipospheres contribute to prolonged drug action, minimizing fluctuations in plasma concentrations and reducing the risk of subtherapeutic dosing. This is particularly beneficial in infections caused by biofilm-forming bacteria, such as *Pseudomonas aeruginosa*, where consistent drug exposure is essential to penetrate biofilm layers and achieve bacterial clearance. The lipid-based delivery system may also enhance penetration into intracellular pathogens, improving efficacy against bacteria that reside within host cells, such as *Salmonella* and *Mycobacterium tuberculosis*.(20)

A significant concern in modern antibiotic therapy is the emergence of bacterial resistance, often linked to suboptimal drug

concentrations and frequent dosing fluctuations. Lipospheres help mitigate this issue by maintaining stable plasma drug levels, reducing selective pressure on bacterial populations, and potentially lowering the likelihood of resistance development. Furthermore, the lipid-based nature of lipospheres may facilitate combination therapy approaches, where norfloxacin is co-encapsulated with resistance-modulating agents such as efflux pump inhibitors or quorum-sensing disruptors, thereby restoring antibiotic susceptibility in resistant bacterial strains.(64)

7.2 Safety and Toxicity Considerations

While liposphere-based formulations offer significant therapeutic benefits, their safety and toxicity profiles must be thoroughly evaluated to ensure clinical viability. The choice of lipid excipients plays a crucial role in determining biocompatibility, as certain lipids may induce immunogenic or inflammatory responses. Generally, biocompatible lipids such as phospholipids, glycerides, and fatty acids are preferred due to their non-toxic and biodegradable nature, minimizing the risk of systemic toxicity. However, careful selection of surfactants and stabilizers is essential, as excessive concentrations of certain emulsifiers may lead to gastrointestinal irritation or hypersensitivity reactions.(65)

Toxicological studies in animal models have demonstrated that lipospheres exhibit a favorable safety profile, with minimal signs of acute or chronic toxicity. However, prolonged exposure to lipid-based carriers may alter lipid metabolism or induce hepatic stress in certain individuals. Therefore, comprehensive preclinical evaluations, including repeated-dose toxicity studies, histopathological assessments, and metabolic profiling, are necessary to ensure safety before advancing to human trials.(66)

Another critical consideration is the potential for lipid oxidation and degradation products, which may compromise the stability and safety of the formulation. To address this, the incorporation of antioxidant stabilizers, such as tocopherols or ascorbic acid derivatives, can help maintain lipid integrity and reduce oxidative stress. Additionally, long-term storage studies must assess whether lipid degradation leads to the formation of toxic byproducts that could affect patient safety.(66)

8. FUTURE PERSPECTIVE

Liposphere-based antibiotic formulations hold immense potential for transforming the landscape of antimicrobial therapy. Future research efforts should focus on optimizing formulation parameters, improving scalability for commercial production, and conducting large-scale clinical trials to validate their therapeutic efficacy. One promising direction is the integration of advanced nanotechnology approaches, such as surface-modified lipospheres or hybrid lipid-polymer systems, which can further enhance drug targeting and controlled release properties. Another area of interest is the development of stimuli-responsive lipospheres that can release norfloxacin in response to specific physiological triggers, such as changes in pH, temperature, or bacterial enzyme activity. Such systems could enable on-demand drug delivery at the site of infection, minimizing off-target effects and reducing systemic toxicity. Additionally, the combination of lipospheres with other drug delivery platforms, such as hydrogels or implantable drug reservoirs, could provide novel solutions for sustained antibiotic therapy in chronic infections.(67) As the global burden of antibiotic resistance continues to rise, there is an urgent need for innovative drug delivery systems that maximize therapeutic outcomes while minimizing resistance development. Lipospheres represent a promising approach, not only for norfloxacin but also for other poorly soluble antibiotics that suffer from bioavailability limitations. By leveraging advances in lipid nanotechnology and formulation science, the next generation of liposphere-based antibiotics could revolutionize the treatment of bacterial infections, improving patient outcomes and addressing critical challenges in antimicrobial resistance.



Fig 4: Development Path and Future Prospects of Lipospheres for Norfloxacin

It outlines the developmental timeline of liposphere-based norfloxacin formulations, from initial research stages to future advancements in site-specific drug delivery and commercialization.(68)

9. CONCLUSION AND FUTURE DIRECTIONS

Lipospheres significantly enhance the oral bioavailability of norfloxacin by improving its solubility, permeability, and sustained systemic retention, resulting in better therapeutic efficacy and reduced dosing frequency. Although promising, challenges such as long-term stability, scalability, and regulatory approval must be addressed through further optimization and clinical validation. Continued research into advanced lipid formulations and targeted delivery strategies will establish lipospheres as a valuable platform in antibiotic therapy, ultimately enhancing treatment outcomes and patient compliance.

Conflict of Interest: No conflict of Interest

Author Contribution: RT- Reviewing the manuscript**, ASB-** Writing the manuscript**, PG-**Final editing and reviewing the manuscript

REFERENCES

[1] Geremia N, Giovagnorio F, Colpani A, De Vito A, Botan A, Stroffolini G, et al. Fluoroquinolones and Biofilm: A Narrative Review. Pharmaceuticals. 2024;17(12):1673.

[2] Sharma D, Patel RP, Zaidi STR, Sarker MMR, Lean QY, Ming LC. Interplay of the Quality of Ciprofloxacin and Antibiotic Resistance in Developing Countries. Frontiers in Pharmacology. 2017;8.

[3] Bush NG, Diez-Santos I, Abbott LR, Maxwell A. Quinolones: Mechanism, Lethality and Their Contributions to Antibiotic Resistance. Molecules. 2020;25(23):5662.

[4] Novelli A, and Rosi E. Pharmacological properties of oral antibiotics for the treatment of uncomplicated urinary tract infections. Journal of Chemotherapy. 2017;29(sup1):10-8.

[5] Shariati A, Arshadi M, Khosrojerdi MA, Abedinzadeh M, Ganjalishahi M, Maleki A, et al. The resistance mechanisms of bacteria against ciprofloxacin and new approaches for enhancing the efficacy of this antibiotic. Frontiers in Public Health. 2022;10.

[6] Markovic M, Zur M, Ragatsky I, Cvijić S, Dahan A. BCS Class IV Oral Drugs and Absorption Windows: Regional-Dependent Intestinal Permeability of Furosemide. Pharmaceutics. 2020;12(12).

[7] Guo M, Sun X, Chen J, Cai T. Pharmaceutical cocrystals: A review of preparations, physicochemical

properties and applications. Acta Pharmaceutica Sinica B. 2021;11(8):2537-64.

[8] Azman M, Sabri AH, Anjani QK, Mustaffa MF, Hamid KA. Intestinal Absorption Study: Challenges and Absorption Enhancement Strategies in Improving Oral Drug Delivery. Pharmaceuticals. 2022;15(8):975.

[9] Khan MA, Khan S, Kazi M, Alshehri SM, Shahid M, Khan SU, et al. Norfloxacin Loaded Lipid Polymer Hybrid Nanoparticles for Oral Administration: Fabrication, Characterization, In Silico Modelling and Toxicity Evaluation. Pharmaceutics. 2021;13(10).

[10] Zhang X, Xing H, Zhao Y, Ma Z. Pharmaceutical Dispersion Techniques for Dissolution and Bioavailability Enhancement of Poorly Water-Soluble Drugs. Pharmaceutics. 2018;10(3).

[11] Nicolaescu OE, Belu I, Mocanu AG, Manda VC, Rău G, Pîrvu AS, et al. Cyclodextrins: Enhancing Drug Delivery, Solubility and Bioavailability for Modern Therapeutics. Pharmaceutics. 2025;17(3):288.

[12] Lopez-Vidal L, Kornelija J, K. RI, A. RD, E. MP, Josefina P, et al. Advanced drug delivery systems for the management of local conditions. Therapeutic Delivery. 2025;16(3):285-303.

[13] Elgart A, Cherniakov I, Aldouby Y, Domb AJ, Hoffman A. Lipospheres and pro-nano lipospheres for delivery of poorly water soluble compounds. Chem Phys Lipids. 2012;165(4):438-53.

[14] Chopra H, Mohanta YK, Rauta PR, Ahmed R, Mahanta S, Mishra PK, et al. An Insight into Advances in Developing Nanotechnology Based Therapeutics, Drug Delivery, Diagnostics and Vaccines: Multidimensional Applications in Tuberculosis Disease Management. Pharmaceuticals. 2023;16(4):581.

[15] Salih Z. Preparation and Characterization of Ganciclovir as Nanostructured Lipid Carrier for Ophthalmic Dosage Form 2022.

[16] Madhusudhan A, Reddy B, Maragoni V, Guttena V. Design and Evaluation of Efavirenz loaded Solid Lipid Nanoparticles to Improve the Oral Bioavailability. 2012;2:84-9.

[17] Maxson T, Mitchell DA. Targeted Treatment for Bacterial Infections: Prospects for Pathogen-Specific Antibiotics Coupled with Rapid Diagnostics. Tetrahedron. 2016;72(25):3609-24.

[18] Yang B, Fang D, Lv Q, Wang Z, Liu Y. Targeted Therapeutic Strategies in the Battle Against Pathogenic Bacteria. Front Pharmacol. 2021;12:673239.

[19] Lin SY. Current and potential applications of simultaneous DSC-FTIR microspectroscopy for pharmaceutical analysis. J Food Drug Anal. 2021;29(2):182-202.

[20] Attama A, Okafor C, Builders P, Okorie O. Formulation and in vitro evaluation of a PEGylated microscopic lipospheres delivery system for ceftriaxone sodium. Drug delivery. 2009;16:448-57.

[21] Mohite P, Singh S, Pawar A, Sangale A, Prajapati BG. Lipid-based oral formulation in capsules to improve the delivery of poorly water-soluble drugs. Frontiers in Drug Delivery. 2023;3.

[22] Ashfaq R, Rasul A, Asghar S, Kovács A, Berkó S, Budai-Szűcs M. Lipid Nanoparticles: An Effective Tool to Improve the Bioavailability of Nutraceuticals. Int J Mol Sci. 2023;24(21).

[23] Alam M, Rizwanullah M, Mir SR, Amin S. Promising prospects of lipid-based topical nanocarriers for the treatment of psoriasis. OpenNano. 2023;10:100123.

[24] Cortesi R, Esposjto E, Luca G, Nastruzzi C. Production of lipospheres as carriers for bioactive compounds. Biomaterials. 2002;23(11):2283-94.

[25] Viegas C, Patrício AB, Prata JM, Nadhman A, Chintamaneni PK, Fonte P. Solid Lipid Nanoparticles vs. Nanostructured Lipid Carriers: A Comparative Review. Pharmaceutics. 2023;15(6):1593.

[26] Bukke SPN, Venkatesh C, Bandenahalli Rajanna S, Saraswathi TS, Kusuma PK, Goruntla N, et al. Solid lipid nanocarriers for drug delivery: design innovations and characterization strategies—a comprehensive review. Discover Applied Sciences. 2024;6(6):279.

[27] Salome Amarachi C, Attama A, Agubata CO, Ogbonna J, Onunkwo G. Recent advances in lipospheres drug delivery system. J Pharm Res. 2012;5:1743-8.

[28] Duong VA, Nguyen TT, Maeng HJ. Preparation of Solid Lipid Nanoparticles and Nanostructured Lipid Carriers for Drug Delivery and the Effects of Preparation Parameters of Solvent Injection Method. Molecules. 2020;25(20).

[29] Khater D, Nsairat H, Odeh F, Saleh M, Jaber A, Alshaer W, et al. Design, Preparation, and Characterization of Effective Dermal and Transdermal Lipid Nanoparticles: A Review. Cosmetics. 2021;8(2):39.

[30] Dudala TB, Yalavarthi PR, Vadlamudi HC, Thanniru J, Yaga G, Mudumala NL, et al. A perspective overview on lipospheres as lipid carrier systems. Int J Pharm Investig. 2014;4(4):149-55.

[31] Urbaniak T, Musiał W. Influence of Solvent Evaporation Technique Parameters on Diameter of Submicron Lamivudine-Poly-ε-Caprolactone Conjugate Particles. Nanomaterials (Basel). 2019;9(9).

[32] Hwisa N, Katakam P, Rao CH, Adiki S. Solvent Evaporation Techniques as Promising Advancement in Microencapsulation. VRI Biological Medicinal Chemistry. 2013;1:8-22.

[33] Ajjarapu S, Banda S, Basim P, Dudhipala N. Melt Fusion Techniques for Solubility Enhancement: A Comparison of Hot Melt Extrusion and KinetiSol® Technologies. Scientia Pharmaceutica. 2022;90(3):51.

[34] Akanda M, Mithu MDSH, Douroumis D. Solid lipid nanoparticles: An effective lipid-based technology for cancer treatment. Journal of Drug Delivery Science and Technology. 2023;86:104709.

[35] Chakravarty P, Famili A, Nagapudi K, Al-Sayah MA. Using Supercritical Fluid Technology as a Green Alternative During the Preparation of Drug Delivery Systems. Pharmaceutics. 2019;11(12).

[36] Kravanja KA, Finšgar M, Knez Ž, Knez Marevci M. Supercritical Fluid Technologies for the Incorporation of Synthetic and Natural Active Compounds into Materials for Drug Formulation and Delivery. Pharmaceutics. 2022;14(8):1670.

[37] Khaw KY, Parat MO, Shaw PN, Falconer JR. Solvent Supercritical Fluid Technologies to Extract Bioactive Compounds from Natural Sources: A Review. Molecules. 2017;22(7).

[38] Khan M, Khan S, Kazi M, Alshehri S, Shahid M, Khan S, et al. Norfloxacin Loaded Lipid Polymer Hybrid Nanoparticles for Oral Administration: Fabrication, Characterization, In Silico Modelling and Toxicity Evaluation. Pharmaceutics. 2021;13:1632.

[39] Poovi G, Damodharan N. Lipid nanoparticles: A challenging approach for oral delivery of BCS Class-II drugs. Future Journal of Pharmaceutical Sciences. 2018;4(2):191-205.

[40] Arora S, Singh B, Kumar S, Kumar A, Singh A, Singh C. Piperine loaded drug delivery systems for improved biomedical applications: Current status and future directions. Health Sciences Review. 2023;9:100138.

[41] Reddy MR, Gubbiyappa KS. Formulation development, optimization and characterization of Pemigatinib-loaded supersaturable self-nanoemulsifying drug delivery systems. Future Journal of Pharmaceutical Sciences. 2022;8(1):45.

[42] NANDINI P, BHIKSHAPATHI D. PREPARATION AND EVALUATION OF ENTRECTINIB PLGA NANOBUBBLES BY CENTRAL COMPOSITE DESIGN. Int J App Pharm. 2025;17(1):304-15.

[43] Alhakamy N, Hosny K, Aldryhim A, Rizg W, Eshmawi B, Bukhary H, et al. Development and optimization of ofloxacin as solid lipid nanoparticles for enhancement of its ocular activity. Journal of Drug Delivery Science and Technology. 2022;72:103373.

[44] Németh Z, Csóka I, Semnani Jazani R, Sipos B, Haspel H, Kozma G, et al. Quality by Design-Driven Zeta Potential Optimisation Study of Liposomes with Charge Imparting Membrane Additives. Pharmaceutics. 2022;14(9).

[45] Karmakar S. Particle Size Distribution and Zeta Potential Based on Dynamic Light Scattering: Techniques to Characterise Stability and Surface distribution of Charged Colloids. 2019. p. 117-59.

[46] Adepu S, Ramakrishna S. Controlled Drug Delivery Systems: Current Status and Future Directions. Molecules. 2021;26(19).

[47] Bayer IS. Controlled Drug Release from Nanoengineered Polysaccharides. Pharmaceutics. 2023;15(5):1364.

[48] Wang E, Qi Z, Cao Y, Li R, Wu J, Tang R, et al. Gels as Promising Delivery Systems: Physicochemical Property Characterization and Recent Applications. Pharmaceutics. 2025;17(2):249.

[49] Santos I, Fawaz F, Lagueny A, Bonini F. Improvement of norfloxacin oral bioavailability by EDTA and sodium caprate. International journal of pharmaceutics. 2003;260:1-4.

[50] Zhao M, Lepak AJ, Andes DR. Animal models in the pharmacokinetic/pharmacodynamic evaluation of antimicrobial agents. Bioorg Med Chem. 2016;24(24):6390-400.

[51] Pachiappan S, K S, M M, Samundi S, Gnanasambandam A. Animal Models Used for Bioavailability and Bioequivalence Studies: Focus on Their Human Likeness. Bioequivalence & Bioavailability International Journal. 2023;7:1-4.

[52] Mendes C, Meirelles GC, Silva MAS, Ponchel G. Intestinal permeability determinants of norfloxacin in Ussing chamber model. Eur J Pharm Sci. 2018;121:236-42.

[53] Bargoni A, Cavalli R, Zara GP, Fundarò A, Caputo O, Gasco M. Transmucosal transport of tobramycin

incorporated in solid lipid nanoparticles (SLN) after duodenal administration to rats. Part II - Tissue distribution. Pharmacological research : the official journal of the Italian Pharmacological Society. 2001;43:497-502.

[54] Nada A, Sharaf M, Gholmy Z, Khalafallah N. Comparative Bioavailability of Norfloxacin Tablets Based on Blood and Urine Data. Medical principles and practice : international journal of the Kuwait University, Health Science Centre. 2007;16:426-31.

[55] Yadav AV, Murthy MS, Shete AS, Sakhare S. Stability aspects of liposome. Indian J Pharm Educ. 2011;45:402-13.

[56] Nasr M, Mansour S, Mortada ND, El Shamy AA. Lipospheres as carriers for topical delivery of aceclofenac: preparation, characterization and in vivo evaluation. AAPS PharmSciTech. 2008;9(1):154-62.

[57] Ramakrishna G, Kakarparthy R. A Review on Lipospheres. Journal of Clinical and Pharmaceutical Research. 2023:8-11.

[58] Singh M, Charde M, Shukla R, Charde RM. Determination of calcipotriene in calcipotriene cream 0.05% w/w by RP-HPLC method development and validation. Research Journal of Pharmacy and Technology. 2011;4:1219-23.

[59] Oliveira PR, Mendes C, Klein L, Sangoi Mda S, Bernardi LS, Silva MA. Formulation development and stability studies of norfloxacin extended-release matrix tablets. Biomed Res Int. 2013;2013:716736.

[60] Das S, Chaudhury A. Recent advances in lipid nanoparticle formulations with solid matrix for oral drug delivery. AAPS PharmSciTech. 2011;12(1):62-76.

[61] Wolska E, Sznitowska M. Modeling the Analysis Process of a Lipid-Based, Multi-Compartment Drug Delivery System. Processes. 2025;13(2):460.

[62] Üner M. Preparation, characterization and physico-chemical properties of solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC): their benefits as colloidal drug carrier systems. Die pharmazie-an international journal of pharmaceutical sciences. 2006;61(5):375-86.

[63] Zong TX, Silveira AP, Morais JAV, Sampaio MC, Muehlmann LA, Zhang J, et al. Recent Advances in Antimicrobial Nano-Drug Delivery Systems. Nanomaterials (Basel). 2022;12(11).

[64] Ventola CL. The antibiotic resistance crisis: part 1: causes and threats. P t. 2015;40(4):277-83.

[65] Iannuccelli V, Sala N, Tursilli R, Coppi G, Scalia S. Influence of liposphere preparation on butyl-methoxydibenzoylmethane photostability. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft für Pharmazeutische Verfahrenstechnik eV. 2006;63:140-5.

[66] Serwecińska L. Antimicrobials and Antibiotic-Resistant Bacteria: A Risk to the Environment and to Public Health. Water. 2020;12(12):3313.

[67] Ferreira M, Ogren M, Dias JNR, Silva M, Gil S, Tavares L, et al. Liposomes as Antibiotic Delivery Systems: A Promising Nanotechnological Strategy against Antimicrobial Resistance. Molecules. 2021;26(7).

[68] Gupta S, Jhawat V. Quality by design (QbD) approach of pharmacogenomics in drug designing and formulation development for optimization of drug delivery systems. Journal of Controlled Release. 2017;245:15-26.